COMPASS Pathways plc (CMPS) stock
CMPSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.98−0.29 (-3.51%)
Close on Nov 17, 2026Market cap $1.11BP/E –Yield –
COMPASS Pathways operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
COMPASS Pathways's operating income for the twelve months ending Jun 30, 2026 was -$181.76M. For fiscal 2025 it was -$179.04M. The highest annual figure on record is -$21.18M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$179.04M | – |
| FY2024 | Dec 31, 2024 | -$178.21M | – |
| FY2023 | Dec 31, 2023 | -$136.92M | – |
| FY2022 | Dec 31, 2022 | -$110.40M | – |
| FY2021 | Dec 31, 2021 | -$83.22M | – |
| FY2020 | Dec 31, 2020 | -$51.39M | – |
| FY2019 | Dec 31, 2019 | -$21.18M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$52.37M | – |
| Q1 FY2026 | Mar 31, 2026 | -$42.90M | – |
| Q4 FY2025 | Dec 31, 2025 | -$45.95M | – |
| Q3 FY2025 | Sep 30, 2025 | -$40.54M | – |
| Q2 FY2025 | Jun 30, 2025 | -$42.93M | – |
| Q1 FY2025 | Mar 31, 2025 | -$49.62M | – |
| Q4 FY2024 | Dec 31, 2024 | -$48.41M | – |
| Q3 FY2024 | Sep 30, 2024 | -$47.90M | – |
| Q2 FY2024 | Jun 30, 2024 | -$43.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.57M | – |
| Q4 FY2023 | Dec 31, 2023 | -$38.41M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.06M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.66M | – |
| Q1 FY2023 | Mar 31, 2023 | -$31.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$32.19M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.54M | – |
| Q2 FY2022 | Jun 30, 2022 | -$27.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.42M | – |
| Q4 FY2021 | Dec 31, 2021 | -$28.32M | – |
| Q3 FY2021 | Sep 30, 2021 | -$21.77M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.53M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.60M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.52M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.48M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.69M | – |
See a number that looks wrong?